These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 29272392

  • 61. Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients.
    Balagopal A, Kandathil AJ, Higgins YH, Wood J, Richer J, Quinn J, Eldred L, Li Z, Ray SC, Sulkowski MS, Thomas DL.
    Hepatology; 2014 Aug; 60(2):477-86. PubMed ID: 24706559
    [Abstract] [Full Text] [Related]

  • 62. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
    Neukam K, Camacho A, Caruz A, Rallón N, Torres-Cornejo A, Rockstroh JK, Macías J, Rivero A, Benito JM, López-Cortés LF, Nattermann J, Gómez-Mateos J, Soriano V, Pineda JA.
    J Hepatol; 2012 Apr; 56(4):788-94. PubMed ID: 22173157
    [Abstract] [Full Text] [Related]

  • 63. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
    Braun DL, Rauch A, Aouri M, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Müllhaupt B, Metzner KJ, Decosterd L, Böni J, Weber R, Fehr J, Swiss HIV Cohort Study.
    PLoS One; 2015 Apr; 10(7):e0133028. PubMed ID: 26176696
    [Abstract] [Full Text] [Related]

  • 64. Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy.
    Murdaca G, Contini P, Cagnati P, Marenco S, Pieri G, Lantieri F, Picciotto A, Puppo F.
    Clin Exp Med; 2017 Feb; 17(1):93-100. PubMed ID: 26567007
    [Abstract] [Full Text] [Related]

  • 65. Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C.
    Labarga P, Fernández-Montero JV, de Mendoza C, Barreiro P, Soriano V.
    Antivir Ther; 2015 Feb; 20(1):65-72. PubMed ID: 25105286
    [Abstract] [Full Text] [Related]

  • 66. The role of insulin resistance in HIV/hepatitis C virus-coinfected patients.
    Eslam M, López-Cortés LF, Romero-Gomez M.
    Curr Opin HIV AIDS; 2011 Nov; 6(6):553-8. PubMed ID: 21934619
    [Abstract] [Full Text] [Related]

  • 67. Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus.
    Backus LI, Boothroyd DB, Phillips BR, Mole LA.
    J Viral Hepat; 2006 Dec; 13(12):799-810. PubMed ID: 17109679
    [Abstract] [Full Text] [Related]

  • 68. An effective interferon-gamma-mediated inhibition of hepatitis C virus replication by natural killer cells is associated with spontaneous clearance of acute hepatitis C in human immunodeficiency virus-positive patients.
    Kokordelis P, Krämer B, Körner C, Boesecke C, Voigt E, Ingiliz P, Glässner A, Eisenhardt M, Wolter F, Kaczmarek D, Nischalke HD, Rockstroh JK, Spengler U, Nattermann J.
    Hepatology; 2014 Mar; 59(3):814-27. PubMed ID: 24382664
    [Abstract] [Full Text] [Related]

  • 69. Brief Report: Reduced Cell-Associated HTLV-2 DNA in Antiretroviral Treated HIV-1-HCV-Coinfected Patients Who Either Received Interferon-α/Ribavirin-Based Hepatitis C Therapy or Had Spontaneous HCV RNA Clearance.
    Abad-Fernández M, Dronda F, Moreno A, Casado JL, Pérez-Elías MJ, Quereda C, Moreno S, Vallejo A.
    J Acquir Immune Defic Syndr; 2015 Jul 01; 69(3):286-90. PubMed ID: 26181704
    [Abstract] [Full Text] [Related]

  • 70. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
    Dominguez S, Ghosn J, Valantin MA, Schruniger A, Simon A, Bonnard P, Caumes E, Pialoux G, Benhamou Y, Thibault V, Katlama C.
    AIDS; 2006 May 12; 20(8):1157-61. PubMed ID: 16691067
    [Abstract] [Full Text] [Related]

  • 71. HCV clearance from saliva of HIV-HCV-coinfected patients on treatment with interferon plus ribavirin.
    Feijoo J, Eirea M, Limeres J, Abeleira M, Ramos I, Ocampo A, Diz P.
    Oral Dis; 2014 Apr 12; 20(3):313-8. PubMed ID: 23607445
    [Abstract] [Full Text] [Related]

  • 72. Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients.
    Kennedy A, Hennessy M, Bergin C, Mulcahy F, Hopkins S, Spiers JP.
    Antivir Ther; 2011 Apr 12; 16(8):1237-47. PubMed ID: 22155905
    [Abstract] [Full Text] [Related]

  • 73. Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients.
    Valerio L, Yazdanpanah Y, Poizot-Martin I, Rosenthal E, Marimoutou C, Gastaut JA, Tran A, Dellamonica P, Freedberg KA, Pradier C.
    J Acquir Immune Defic Syndr; 2008 Jan 01; 47(1):50-5. PubMed ID: 18156991
    [Abstract] [Full Text] [Related]

  • 74. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial.
    Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, Chan ES, Schooley RT, Rinaldo CR, Thielman N, Li XD, Wahl SM, Shore J, Janik J, Lempicki RA, Simpson Y, Pollard RB, AIDS Clinical Trials Group A5192 Team.
    J Infect Dis; 2010 Jun 01; 201(11):1686-96. PubMed ID: 20420510
    [Abstract] [Full Text] [Related]

  • 75. Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort.
    Vogel M, Dominguez S, Bhagani S, Azwa A, Page E, Guiguet M, Valantin MA, Katlama C, Rockstroh JK, Nelson M.
    Antivir Ther; 2010 Jun 01; 15(2):267-79. PubMed ID: 20386082
    [Abstract] [Full Text] [Related]

  • 76. Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection.
    Neukam K, Munteanu D, Haubitz S, Mira JA, Ingiliz P, Rivero-Juárez A, Lutz T, de los Santos-Gil I, Scholten S, Márquez M, Rauch A, Rockstroh JK, Pineda JA.
    Antivir Ther; 2015 Jun 01; 20(4):407-13. PubMed ID: 25470790
    [Abstract] [Full Text] [Related]

  • 77. Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8+ T Cells.
    Kwaa AKR, Talana CAG, Blankson JN.
    J Virol; 2019 Feb 01; 93(3):. PubMed ID: 30404799
    [Abstract] [Full Text] [Related]

  • 78. Changes in hepatitis C virus (HCV) viral load and interferon-alpha levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy.
    Bower WA, Culver DH, Castor D, Wu Y, James VN, Zheng H, Hammer S, Kuhnert WL, Williams IT, Bell BP, Vlahov D, Dezzutti CS.
    J Acquir Immune Defic Syndr; 2006 Jul 01; 42(3):293-7. PubMed ID: 16763522
    [Abstract] [Full Text] [Related]

  • 79. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T.
    AIDS; 2004 Jan 02; 18(1):75-9. PubMed ID: 15090832
    [Abstract] [Full Text] [Related]

  • 80. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
    Zylberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, Bochet M, Poynard T, Katlama C, Pialoux G, Bréchot C, Pol S.
    Gut; 2000 Nov 02; 47(5):694-7. PubMed ID: 11034587
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.